Global Newborn Screening for SMA and SCID Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Newborn Screening for SMA and SCID Market 2023 by Company, Regions, Type and Application, Forecast to 2029

According to our (Global Info Research) latest study, the global Newborn Screening for SMA and SCID market size was valued at USD 133 million in 2022 and is forecast to a readjusted size of USD 276.3 million by 2029 with a CAGR of 11.0% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global key players providing newborn screening for SMA and SCID are Perkinelmer, Thermo Fisher, ImmunoIVD, and Labsystems Diagnostics. The top four companies together hold 90% of the market share, with the largest vendor being Perkinelmer with 60% of the market share. The global companies providing newborn SMA and SCID screening are mainly located in North America and Europe, with North America holding the largest market share with 60%. In terms of product categories, kits dominate the market with 60% market share, followed by instruments and software with 35% and 5% market share, respectively. In terms of applications, SCID screening holds a 65% market share, while SMA screening is 35%.

Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth.

Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections.

Spinal muscular atrophy (SMA) is a group of hereditary diseases that progressively destroys motor neurons—nerve cells in the brain stem and spinal cord that control essential skeletal muscle activity such as speaking, walking, breathing, and swallowing, leading to muscle weakness and atrophy.

This report is a detailed and comprehensive analysis for global Newborn Screening for SMA and SCID market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Newborn Screening for SMA and SCID market size and forecasts, in consumption value ($ Million), 2018-2029

Global Newborn Screening for SMA and SCID market size and forecasts by region and country, in consumption value ($ Million), 2018-2029

Global Newborn Screening for SMA and SCID market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029

Global Newborn Screening for SMA and SCID market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Newborn Screening for SMA and SCID

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Newborn Screening for SMA and SCID market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Perkinelmer, Thermo Fisher, ImmunoIVD and Labsystems Diagnostics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Newborn Screening for SMA and SCID market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Instruments
Kits
Software

Market segment by Application
SCID Screening
SMA Screening

Market segment by players, this report covers
Perkinelmer
Thermo Fisher
ImmunoIVD
Labsystems Diagnostics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Newborn Screening for SMA and SCID product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Newborn Screening for SMA and SCID, with revenue, gross margin and global market share of Newborn Screening for SMA and SCID from 2018 to 2023.

Chapter 3, the Newborn Screening for SMA and SCID competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Newborn Screening for SMA and SCID market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Newborn Screening for SMA and SCID.

Chapter 13, to describe Newborn Screening for SMA and SCID research findings and conclusion.